US 11,890,310 B2
Pharmaceutical composition and method of manufacturing
Gary J. Speier, Maple Grove, MN (US)
Filed by Avenir Wellness Solutions, Inc., Sherman Oaks, CA (US)
Filed on May 12, 2022, as Appl. No. 17/663,164.
Application 17/663,164 is a continuation of application No. 16/856,492, filed on Apr. 23, 2020, granted, now 11,344,591.
Application 16/856,492 is a continuation of application No. 16/809,700, filed on Mar. 5, 2020, granted, now 11,478,520.
Application 16/809,700 is a continuation of application No. 16/359,579, filed on Mar. 20, 2019, granted, now 10,624,940, issued on Apr. 21, 2020.
Application 16/359,579 is a continuation of application No. 14/934,940, filed on Nov. 6, 2015, granted, now 10,238,705, issued on Mar. 26, 2019.
Application 14/934,940 is a continuation of application No. 14/723,980, filed on May 28, 2015, granted, now 9,186,386, issued on Nov. 17, 2015.
Application 14/723,980 is a continuation in part of application No. 14/694,303, filed on Apr. 23, 2015, granted, now 9,980,996, issued on May 29, 2018.
Application 14/694,303 is a continuation of application No. 14/255,296, filed on Apr. 17, 2014, granted, now 9,044,390, issued on Jun. 2, 2015.
Prior Publication US 2022/0280582 A1, Sep. 8, 2022
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 36/185 (2006.01); A61K 36/00 (2006.01); A61K 9/00 (2006.01); A61K 9/70 (2006.01); A61K 31/352 (2006.01); A61K 31/05 (2006.01); B01D 11/04 (2006.01); A61K 31/00 (2006.01)
CPC A61K 36/185 (2013.01) [A61K 9/006 (2013.01); A61K 9/7023 (2013.01); A61K 31/00 (2013.01); A61K 31/05 (2013.01); A61K 31/352 (2013.01); B01D 11/0407 (2013.01); A61K 2236/00 (2013.01)] 26 Claims
 
1. A process for obtaining a first extract of Cannabis sativa, Cannabis indica, or combination thereof, enriched with at least one of: cannabinol; cannabinolic acid;
Δ(9)-tetrahydrocannabinolic acid; Δ(9)-cannabidiol; Δ(9)-tetrahydrocannabidiolic acid;
Δ(8)-tetrahydrocannabinolic acid; Δ(8)-tetrahydrocannabidiol; Δ(8)-tetrahydrocannabidiolic acid; Δ(9)-tetrahydrocannabivarin; cannabigerol; cannabigerolic acid; cannabichromene; cannabichromenic acid; cannabicyclol; and cannabicyclolic acid, and
a second extract of Cannabis sativa, Cannabis indica, or combination thereof, enriched with at least one of Δ(8)-tetrahydrocannabinol and Δ(9)-tetrahydrocannabinol, the process comprising:
(a) contacting Cannabis sativa, Cannabis indica, or a combination thereof, with carbon dioxide as the sole supercritical fluid solvent, at a pressure of 1,400 psi to 3,800 psi, at a temperature of 35° C. to 65° C., for a period of time of 1.5 hours to 8.5 hours, to provide an enriched extract of Cannabis sativa, Cannabis indica, or combination thereof; and
(b) removing the supercritical carbon dioxide from the extract; wherein the (a) contacting of the Cannabis sativa, Cannabis indica, or a combination thereof, with the supercritical carbon dioxide and then the (b) removing the supercritical carbon dioxide, is carried out two or more times, such that the process is a supercritical carbon dioxide fluid extraction;
wherein a first supercritical carbon dioxide fluid extraction is carried out such that:
(i) the contacting of the Cannabis sativa, Cannabis indica, or a combination thereof, with the supercritical carbon dioxide, is carried out at a pressure of 1,600 psi to 2,000 psi, at a temperature of 44° C. to 54° C., for a period of time of 1.5 hours to 4.5 hours, to provide the first extract;
wherein a second supercritical carbon dioxide fluid extraction is carried out such that:
(i) the contacting of the Cannabis sativa, Cannabis indica, or a combination thereof, with the supercritical carbon dioxide, is carried out at a pressure of 2,250 psi to 3,800 psi, at a temperature of 44° C. to 54° C., for a period of time of 3.5 hours to 8.5 hours, to provide a second extract.